NCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
42 trialsNCT05211323 2026-04-13
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
NCT06096779 2026-04-03
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT03937830 2026-03-24
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
NCT05337137 2026-01-12
RELATIVITY-106
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06478693 2025-12-18
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Myeloid Therapeutics
Phase 1 Recruiting
NCT06680258 2025-09-03
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Tempest Therapeutics
Phase 3 Not yet recruiting
NCT05992220 2025-02-21
ALERT-HCC
Asan Medical Center
Phase 2 Recruiting
NCT05717400 2024-12-31
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
M.D. Anderson Cancer Center
Phase 4 Terminated
NCT06584071 2024-12-16
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Biotheus Inc.
Phase 1/2 Not yet recruiting
NCT06725121 2024-12-16
MacroTrans
University Health Network, Toronto
Phase 1/2 Recruiting
NCT00410956 2024-12-10
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06492408 2024-07-09
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06482801 2024-07-01
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06408623 2024-05-10
Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06265350 2024-02-20
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
Sun Yat-sen University
Phase NA Recruiting
NCT05510427 2023-08-15
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05109052 2023-07-13
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
University of Rochester
Phase 1/2 Withdrawn
NCT05185505 2023-02-01
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
The Methodist Hospital Research Institute
Phase 4 Recruiting
NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05093608 2022-10-17
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT00867321 2022-04-19
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00335829 2021-08-13
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Yale University
Phase 2 Completed
NCT04627363 2020-11-13
HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
Sun Yat-sen University
Phase 2 Unknown
NCT00049322 2020-09-01
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown
NCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00980239 2015-11-11
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00576199 2014-08-29
A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00605722 2014-07-14
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT02013830 2014-06-06
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00467194 2013-06-17
Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Centre, Singapore
Phase 1 Completed
NCT00242502 2013-05-06
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00426829 2012-08-01
Proton Therapy and Bevacizumab for Primary Liver Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00507585 2012-07-30
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00775073 2012-04-30
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Treiber, Gerhard
Phase 2 Completed
NCT00659022 2011-09-12
Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth
Radboud University Medical Center
Phase 2 Unknown
NCT00106054 2010-08-27
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
Pfizer
Phase 2 Terminated